SEC Reports
1
GLPG
Lakefront Biotherapeutics NV
—
12-mo target$27.19 (-2.0%)
Biotech & Drug Discovery
Snapshot
The big-picture read on GLPG right now — valuation, ownership and activity at a glance.
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Analyst ratings buy % +6.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Feb 25, 2026 | RBC Capital | MAINTAIN | Sector Perform | 55% |
| Nov 7, 2025 | RBC Capital | MAINTAIN | Sector Perform | 55% |
| Oct 22, 2025 | RBC Capital | MAINTAIN | Sector Perform | 55% |
| Oct 21, 2025 | Leerink Partners | UPGRADE | Outperform | 49% |
| Feb 14, 2025 | Morgan Stanley | DOWNGRADE | Underweight | 55% |
| Jan 23, 2025 | Barclays | DOWNGRADE | Underweight | 54% |
| Nov 1, 2024 | RBC Capital | MAINTAIN | Sector Perform | 55% |
| Sep 9, 2024 | Leerink Partners | INITIATE | Market Perform | 49% |
| Apr 22, 2024 | Morgan Stanley | MAINTAIN | Equal-Weight | 55% |
| Apr 1, 2024 | B of A Securities | DOWNGRADE | Underperform | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 1 | 6 | 6 | 3 | 17% | |
| Aug 1, 2026 | 2 | 1 | 6 | 6 | 3 | 17% | |
| Jul 1, 2026 | 2 | 1 | 6 | 6 | 3 | 17% | |
| Jun 1, 2026 | 2 | 1 | 6 | 6 | 3 | 17% | |
| May 1, 2026 | 2 | 1 | 6 | 6 | 3 | 17% | |
| Apr 1, 2026 | 2 | 1 | 6 | 6 | 3 | 17% | |
| Mar 1, 2026 | 2 | 1 | 6 | 6 | 3 | 17% | |
| Feb 1, 2026 | 2 | 1 | 6 | 7 | 3 | 16% |
Price targets
Where 1 covering analysts think GLPG trades over the next 12 months.
$27.19 -2.0% upside Hold
Current$27.73 Low$27.19 Median$27.19 High$27.19 1 analysts
$27.19$27.19
Analyst rating None as of Jul 8, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
1 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 1 neutral · avg impact 4.0/10.
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Jul 21, 2026
Clinical Trial
A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma
Phase Phase 2 — TERMINATED
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-6.24 | $-11.71–$-0.77 | -569.1% | -985.2% | 0↑ 2↓ | $0.0B | 2 |
| Next Q | $-0.77 | $-0.87–$-0.66 | -329.8% | -36.6% | 0↑ 2↓ | $0.0B | 2 |
| Current FY | $-6.22 | $-14.15–$-1.18 | -161.0% | -136.6% | 0↑ 2↓ | $0.3B | 3 |
| Next FY | $-1.36 | $-4.03–$0.35 | 78.1% | -95.7% | 0↑ 2↓ | $0.2B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-6.240 | — |
| 7d ago | $-0.575 | -5.665 |
| 30d ago | $-0.575 | -5.665 |
| 60d ago | $0.280 | -6.520 |
| 90d ago | $0.280 | -6.520 |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for GLPG.
Shares short
1,435,699
Settlement Apr 30, 2026
Change vs prior
+4.7%
Semi-monthly cycle
Days to cover
11.2
At avg daily volume
All GLPG filing & press-release reports (1)
- 6-K reportMay 27, 2026